Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
timolol/dorzolamide combination · 2 trials · 2 indications
The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant.
| Arm | Type | Description |
|---|---|---|
| Timolol/Dorzolamide | EXPERIMENTAL | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| MK0507A, dorzolamide hydrochloride (+) timolol maleate | DRUG | - |
| Comparator: timolol maleate | DRUG | - |
| Duration of Treatment: Part 1) 6 wk timolol maleate run in | DRUG | - |
| Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds | DRUG | - |
| timolol/dorzolamide combination | DRUG | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
Inclusion Criteria: * Patients with glaucoma or ocular hypertension Exclusion Criteria: * Other eye conditions * Poor vision * Recent eye surgery * Use of contact lenses * Nursing or pregnant women * Use of some other selected medications * Drug or alcohol abuse * Asthma * Slow heart beat * Aller...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Timolol/dorzolamide combination is used for glaucoma, including ocular hypertension. It is a fixed-dose combination eye drop being developed by Merck & Company, Inc. (MRK) as a small molecule therapy in the ophthalmology therapeutic area. The drug is currently in clinical development and is not approved.
Merck & Company, Inc. (MRK) is developing timolol/dorzolamide combination. The drug is a small molecule combination therapy for glaucoma and ocular hypertension. It is being studied in clinical trials, including a completed Phase 3 study, but it is not yet approved.
Timolol/dorzolamide combination is in Phase 3 clinical development. One completed Phase 3 trial (NCT00108017) enrolled 330 patients with glaucoma or ocular hypertension. A second completed Phase 2 trial (NCT00832377) studied 37 patients with normal tension glaucoma. The drug remains investigational.
Timolol/dorzolamide combination has two completed clinical trials. NCT00108017 was a Phase 3 study comparing the effects of two glaucoma drugs over 24 hours in 330 patients with glaucoma or ocular hypertension. NCT00832377 was a Phase 2 study in 37 patients with normal tension glaucoma. Both trials are completed.
Yes, timolol/dorzolamide combination is also known as COSOPT. The Phase 2 trial NCT00832377 is titled 'COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study,' confirming that COSOPT is the brand name for this combination therapy.